JP2006523224A5 - - Google Patents

Download PDF

Info

Publication number
JP2006523224A5
JP2006523224A5 JP2006508920A JP2006508920A JP2006523224A5 JP 2006523224 A5 JP2006523224 A5 JP 2006523224A5 JP 2006508920 A JP2006508920 A JP 2006508920A JP 2006508920 A JP2006508920 A JP 2006508920A JP 2006523224 A5 JP2006523224 A5 JP 2006523224A5
Authority
JP
Japan
Prior art keywords
antigen
composition
vsv
dna plasmid
cytokine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2006508920A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006523224A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2004/006089 external-priority patent/WO2004093906A1/en
Publication of JP2006523224A publication Critical patent/JP2006523224A/ja
Publication of JP2006523224A5 publication Critical patent/JP2006523224A5/ja
Withdrawn legal-status Critical Current

Links

JP2006508920A 2003-03-26 2004-03-23 免疫原性組成物および方法 Withdrawn JP2006523224A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US45787603P 2003-03-26 2003-03-26
US54673304P 2004-02-23 2004-02-23
PCT/US2004/006089 WO2004093906A1 (en) 2003-03-26 2004-03-23 Immunogenic composition and methods

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2011154426A Division JP5635950B2 (ja) 2003-03-26 2011-07-13 免疫原性組成物および方法

Publications (2)

Publication Number Publication Date
JP2006523224A JP2006523224A (ja) 2006-10-12
JP2006523224A5 true JP2006523224A5 (cg-RX-API-DMAC7.html) 2007-05-24

Family

ID=42828775

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006508920A Withdrawn JP2006523224A (ja) 2003-03-26 2004-03-23 免疫原性組成物および方法

Country Status (13)

Country Link
US (2) US20070134200A1 (cg-RX-API-DMAC7.html)
EP (1) EP1605971B1 (cg-RX-API-DMAC7.html)
JP (1) JP2006523224A (cg-RX-API-DMAC7.html)
CN (1) CN1764474B (cg-RX-API-DMAC7.html)
AT (1) ATE468859T1 (cg-RX-API-DMAC7.html)
AU (1) AU2004231464B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0408779A (cg-RX-API-DMAC7.html)
CA (1) CA2517010C (cg-RX-API-DMAC7.html)
DK (1) DK1605971T3 (cg-RX-API-DMAC7.html)
MX (1) MXPA05008526A (cg-RX-API-DMAC7.html)
NZ (1) NZ542652A (cg-RX-API-DMAC7.html)
PL (1) PL1605971T3 (cg-RX-API-DMAC7.html)
WO (1) WO2004093906A1 (cg-RX-API-DMAC7.html)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6861422B2 (en) 2003-02-26 2005-03-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions
ES2345198T3 (es) * 2003-03-26 2010-09-17 Wyeth Llc Composicion y procedimientos inmunologicos.
TW200613554A (en) * 2004-06-17 2006-05-01 Wyeth Corp Plasmid having three complete transcriptional units and immunogenic compositions for inducing an immune response to HIV
DE102004029784A1 (de) 2004-06-21 2006-01-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue 2-Benzylaminodihydropteridinone, Verfahren zur deren Herstellung und deren Verwendung als Arzneimittel
DE102004033670A1 (de) 2004-07-09 2006-02-02 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Pyridodihydropyrazinone, Verfahren zu Ihrer Herstellung und Ihre Verwendung als Arzneimittel
US7728134B2 (en) 2004-08-14 2010-06-01 Boehringer Ingelheim International Gmbh Hydrates and polymorphs of 4[[(7R)-8-cyclopentyl-7-ethyl-5,6,7,8-tetrahydro-5-methyl-6-oxo-2-pteridinyl]amino]-3-methoxy-N-(1-methyl-4-piperidinyl)-benzamide, process for their manufacture and their use as medicament
US20060035903A1 (en) 2004-08-14 2006-02-16 Boehringer Ingelheim International Gmbh Storage stable perfusion solution for dihydropteridinones
US7759485B2 (en) 2004-08-14 2010-07-20 Boehringer Ingelheim International Gmbh Process for the manufacture of dihydropteridinones
US20060074088A1 (en) 2004-08-14 2006-04-06 Boehringer Ingelheim International Gmbh Dihydropteridinones for the treatment of cancer diseases
US20060058311A1 (en) 2004-08-14 2006-03-16 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation
EP1630163A1 (de) 2004-08-25 2006-03-01 Boehringer Ingelheim Pharma GmbH & Co.KG Dihydropteridinonderivative, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
DE102004058337A1 (de) 2004-12-02 2006-06-14 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung von annelierten Piperazin-2-on Derivaten
WO2006110344A1 (en) * 2005-04-07 2006-10-19 Wyeth Novel methods for inducing an immune response against human immunodefiency virus
US7439358B2 (en) 2006-02-08 2008-10-21 Boehringer Ingelheim International Gmbh Specific salt, anhydrous and crystalline form of a dihydropteridione derivative
EP2185559A1 (en) 2007-08-03 2010-05-19 Boehringer Ingelheim International GmbH Crystalline form of a dihydropteridione derivative
KR101723900B1 (ko) * 2009-06-08 2017-04-07 더 유니버시티 오브 웨스트 온타리오 면역화 요법용 발현 벡터로서의 수포성 구내염 바이러스의 상이한 혈청형
CN102803502B (zh) * 2009-09-29 2019-06-04 宾夕法尼亚大学理事会 用于诊断和治疗脑炎或癫痫的方法
US8546566B2 (en) 2010-10-12 2013-10-01 Boehringer Ingelheim International Gmbh Process for manufacturing dihydropteridinones and intermediates thereof
US9358233B2 (en) 2010-11-29 2016-06-07 Boehringer Ingelheim International Gmbh Method for treating acute myeloid leukemia
SI2654785T1 (sl) * 2010-12-22 2019-06-28 Bayer Intellectual Property Gmbh Ojačan imunski odziv pri govejih vrstah
US9370535B2 (en) 2011-05-17 2016-06-21 Boehringer Ingelheim International Gmbh Method for treatment of advanced solid tumors
JP2016525532A (ja) 2013-07-26 2016-08-25 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 骨髄異形成症候群の処置
CA2940794C (en) 2014-02-28 2022-05-31 Bayer Animal Health Gmbh Immunostimulatory plasmids
AU2015225553B2 (en) * 2014-03-01 2020-02-27 Profectus Biosciences, Inc. Recombinant Isfahan viral vectors
US9867831B2 (en) 2014-10-01 2018-01-16 Boehringer Ingelheim International Gmbh Combination treatment of acute myeloid leukemia and myelodysplastic syndrome
TW201718001A (zh) 2015-07-31 2017-06-01 拜耳動物保健有限公司 豬物種中增強之免疫反應
CN105567646B (zh) * 2016-02-22 2019-01-01 浙江大学 分泌抗甘蔗花叶病毒单抗杂交瘤细胞株及其单抗应用
CN113968907B (zh) * 2020-07-22 2023-05-26 中国人民解放军军事科学院军事医学研究院 具有中和活性的抗尼帕病毒单克隆抗体及应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
YU44186B (en) * 1978-12-22 1990-04-30 Biogen Nv Process for obtaining recombinant dnk molecules
US5703055A (en) * 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5593972A (en) * 1993-01-26 1997-01-14 The Wistar Institute Genetic immunization
US7153510B1 (en) * 1995-05-04 2006-12-26 Yale University Recombinant vesiculoviruses and their uses
US20040013684A1 (en) * 2000-04-27 2004-01-22 Benjamin Rovinski Immunizing against hiv infection
US20030021805A1 (en) * 2001-05-29 2003-01-30 Barber Glen N. Generation of HCV-like particles and chimeric HCV virus
CA2452517A1 (en) * 2001-07-11 2003-01-23 University Of Miami Recombinant vsv for the treatment of tumor cells

Similar Documents

Publication Publication Date Title
Kalams et al. Safety and immunogenicity of an HIV-1 gag DNA vaccine with or without IL-12 and/or IL-15 plasmid cytokine adjuvant in healthy, HIV-1 uninfected adults
Kent et al. Enhanced T-cell immunogenicity and protective efficacy of a human immunodeficiency virus type 1 vaccine regimen consisting of consecutive priming with DNA and boosting with recombinant fowlpox virus
Fuchs et al. First-in-human evaluation of the safety and immunogenicity of a recombinant vesicular stomatitis virus human immunodeficiency virus-1 gag vaccine (HVTN 090)
Earl et al. Immunogenicity and protective efficacy of oligomeric human immunodeficiency virus type 1 gp140
Goepfert et al. Specificity and 6-month durability of immune responses induced by DNA and recombinant modified vaccinia Ankara vaccines expressing HIV-1 virus-like particles
Lorin et al. A single injection of recombinant measles virus vaccines expressing human immunodeficiency virus (HIV) type 1 clade B envelope glycoproteins induces neutralizing antibodies and cellular immune responses to HIV
Barouch et al. A human T-cell leukemia virus type 1 regulatory element enhances the immunogenicity of human immunodeficiency virus type 1 DNA vaccines in mice and nonhuman primates
Bansal et al. Multifunctional T-cell characteristics induced by a polyvalent DNA prime/protein boost human immunodeficiency virus type 1 vaccine regimen given to healthy adults are dependent on the route and dose of administration
Barouch et al. Elicitation of high-frequency cytotoxic T-lymphocyte responses against both dominant and subdominant simian-human immunodeficiency virus epitopes by DNA vaccination of rhesus monkeys
Wu et al. Enhanced breadth of CD4 T-cell immunity by DNA prime and adenovirus boost immunization to human immunodeficiency virus Env and Gag immunogens
Mehendale et al. Safety and immunogenicity of DNA and MVA HIV-1 subtype C vaccine prime-boost regimens: a phase I randomised Trial in HIV-uninfected Indian volunteers
CN1764474B (zh) 免疫原性组合物及方法
Nilsson et al. HIV-DNA given with or without intradermal electroporation is safe and highly immunogenic in healthy Swedish HIV-1 DNA/MVA vaccinees: a phase I randomized trial
Voss et al. Prevention of disease induced by a partially heterologous AIDS virus in rhesus monkeys by using an adjuvanted multicomponent protein vaccine
Hartnell et al. A novel vaccine strategy employing serologically different chimpanzee adenoviral vectors for the prevention of HIV-1 and HCV coinfection
Spearman HIV vaccine development: lessons from the past and promise for the future
CA2419822A1 (en) Modifications of hiv env, gag, and pol enhance immunogenicity for genetic immunization
Ake et al. Safety and immunogenicity of PENNVAX-G DNA prime administered by Biojector 2000 or CELLECTRA electroporation device with modified vaccinia Ankara-CMDR boost
JP2013507107A5 (cg-RX-API-DMAC7.html)
Iyer et al. DNA/MVA Vaccines for HIV/AIDS
Malkevitch et al. A call for replicating vector prime-protein boost strategies in HIV vaccine design
Otten et al. Induction of broad and potent anti-human immunodeficiency virus immune responses in rhesus macaques by priming with a DNA vaccine and boosting with protein-adsorbed polylactide coglycolide microparticles
Poles et al. Induction of intestinal immunity by mucosal vaccines as a means of controlling HIV infection
Khattar et al. Enhanced immune responses to HIV-1 envelope elicited by a vaccine regimen consisting of priming with Newcastle disease virus expressing HIV gp160 and boosting with gp120 and SOSIP gp140 proteins
Kaulfuß et al. Induction of complex immune responses and strong protection against retrovirus challenge by adenovirus-based immunization depends on the order of vaccine delivery